Cara Therapeutics (STU:69C) ROE % Adjusted to Book Value : -35.90% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Cara Therapeutics ROE % Adjusted to Book Value?

Cara Therapeutics's ROE % for the quarter that ended in Sep. 2024 was -788.01%. Cara Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 21.95. Cara Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -35.90%.

Cara Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Cara Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics ROE % Adjusted to Book Value Chart

Cara Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-16.52

1.24

-13.67

-12.73

-147.23

Cara Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-109.65	-245.08	-180.40	-274.29	-35.90

Competitive Comparison of Cara Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Cara Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cara Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's ROE % Adjusted to Book Value falls into.

Cara Therapeutics ROE % Adjusted to Book Value Calculation

Cara Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-107.48%	/	0.73
	=	-147.23%

Cara Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-788.01%	/	21.95
	=	-35.90%

Cara Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Cara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (STU:69C) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CARA:USA 0HTC:UK 69C:Germany

Address

400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901

Website

https://www.caratherapeutics.com

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Cara Therapeutics Headlines

No Headlines